The research behind all Pergamums’ development projects come from discoveries and innovations done by research groups at Swedens’ leading university hospitals.
Pergamum was formed by merging and integrating three biotechs; PharmaSurgics in Sweden AB, DermaGen AB, and Lipopeptide AB into one operational company and the corporate office is located in Solna, Sweden.
CURRENT OWNERS OF PERGAMUM
Karolinska Development aims to create value for patients, researchers, and investors by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.
Midroc New Technology AB
Midroc New Technology AB is a Swedish early stage Venture Capital Company devoted to providing equity capital and business expertise to ground-breaking technologies and companies that have the demonstrated potential to enable a better future on a global scale.
Östersjöstiftelsen (The Foundation for Baltic and East European Studies) was founded by the Swedish Government in 1994. Its mission is to support research and doctoral studies, as well as the academic infrastructure at Södertörns högskola (Södertörn University).